Sage Journals: Discover world-class research

Retricted access

Research article

First published 2004-4

Interpretation of Drug Risk and Benefit: Individual and Population Perspectives

Darrel C Bjornson

Annals of Pharmacotherapy

Retricted access

Other

First published 1993-10

Risk/Benefit Assessment: The “Greased Pig” of Drug Development

Loren L. Miller

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2014-3

Quantitative Drug Benefit-Risk Assessment

Victor Crentsil, Jung Lee, Andre Jackson

Annals of Pharmacotherapy

Retricted access

Other

First published 1998-4

The Effect of Pharmacy Benefit Manager Clinical Programs and Services on Access to Prescription Drug Benefit Coverage

J. Russell Teagarden

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2014-5

Association between Prescription Drug Benefit and Hospital Readmission Rates

Laura Challen, Christine Kelso, Bhumi Gandhi

Hospital Pharmacy

Retricted access

Other

First published 2001-4

Pharmacy Benefit Managers and Medicare Beneficiary Access to Prescription Drugs

Joshua Cohen, Jennifer Chee

Therapeutic Innovation & Regulatory Science

Open access

Research article

First published 2013-6

Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users

Celia JA Morgan, Louise A Noronha, Mark Muetzelfeldt [...]

Journal of Psychopharmacology

Retricted access

Other

First published 2005-7

Placement of Benefits and Risks in Prescription Drug Manufacturers' Websites and Information Source Expectations

Kevin E. Hicks, Michael S. Wogalter, William J. Vigilante

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2003-3

Effects of Losing SSI Benefits on Standard Drug and Alcohol Outcome Measures

Joseph Guydish, Claudia Ponath, Alan Bostrom [...]

Contemporary Drug Problems

Retricted access

Other

First published 1993-10

Risk/Benefit Assessment of New Drugs: Perspectives of a Former FDA Advisory Committee Member

James H. Lewis

Therapeutic Innovation & Regulatory Science

Search results